Evidence map›Paper›PMID 36544780›Full record

ArticleFrontiers in immunology2022

High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells.

Chansavath Phetsouphanh, Weng Hua Khoo, Katherine Jackson, Vera Klemm, Annett Howe, Anupriya Aggarwal, Anouschka Akerman, Vanessa Milogiannakis, Alberto Ospina Stella, Romain Rouet and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Cytotoxic CD4Signal transduction and targeted therapy · 2026
    Review
  2. Expanded CD16Scientific reports · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 5 institutions in 1 country.

Chansavath PhetsouphanhKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Weng Hua KhooGarvan Institute of Medical Research, Sydney, NSW, Australia.
Katherine JacksonGarvan Institute of Medical Research, Sydney, NSW, Australia.
Vera KlemmKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Annett HoweKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Anupriya AggarwalKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Anouschka AkermanKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Vanessa MilogiannakisKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Alberto Ospina StellaKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Romain RouetGarvan Institute of Medical Research, Sydney, NSW, Australia.
Peter SchofieldGarvan Institute of Medical Research, Sydney, NSW, Australia.
Megan L FaulksGarvan Institute of Medical Research, Sydney, NSW, Australia.
Hannah LawKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Thidarat DanwilaiNSW State Reference Laboratory for HIV, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.
Mitchell StarrNSW State Reference Laboratory for HIV, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.
C Mee Ling MunierKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Daniel ChristGarvan Institute of Medical Research, Sydney, NSW, Australia.
Mandeep SinghGarvan Institute of Medical Research, Sydney, NSW, Australia.
Peter I CroucherGarvan Institute of Medical Research, Sydney, NSW, Australia.
Fabienne Brilot-TurvilleBrain and Mind Centre, Children's Hospital at Westmead, University of Sydney, Sydney, NSW, Australia.
Stuart TurvilleKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Tri Giang PhanGarvan Institute of Medical Research, Sydney, NSW, Australia.
Gregory J DoreKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
David DarleyDepartment of Infectious Diseases, St. Vincent's Hospital, Sydney, NSW, Australia.
Philip CunninghamNSW State Reference Laboratory for HIV, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.
Gail V MatthewsKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
Anthony D KelleherKirby Institute, University of New South Wales (UNSW), Sydney, NSW, Australia.
John J ZaundersNSW State Reference Laboratory for HIV, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.
UNSW Sydney · AUGarvan Institute of Medical Research · AUSt Vincent's Hospital Sydney · AUChildren's Hospital at Westmead · AUSt Vincent's Clinic · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Long-term immunity to SARS-CoV-2 infection, including neutralizing antibodies and T cell-mediated immunity, is required in a very large majority of the population in order to reduce ongoing disease burden. Methods: We have investigated the association between memory CD4 and CD8 T cells and levels of neutralizing antibodies in convalescent COVID-19 subjects. Findings: Higher titres of convalescent neutralizing antibodies were associated with significantly higher levels of RBD-specific CD4 T cells, including specific memory cells that proliferated vigorously Interpretation: Our results suggest that targeting CD4 T cell epitopes proximal to and within the RBD-region should be prioritized in booster vaccines.

Indexed as

CD4-Positive T-LymphocytesCOVID-19Antibodies, NeutralizingEpitopes, T-LymphocyteHumansSARS-CoV-2Antibodies, NeutralizingEpitopes, T-LymphocyteCD4 functionCD4 T cellsneutralizing antibodiesproliferationSARS-CoV-2

Identifiers

PMID36544780
PMCPMC9762180
OpenAlexW4311545700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.